ReviewEndocrinology and metabolism (Seoul, Korea)2016
Endocrine Risk Factors for Cognitive Impairment.
Review in Endocrinology and metabolism (Seoul, Korea), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Cognitive impairment in idiopathic intracranial hypertension: A conceptual framework and therapeutic implications.Surgical neurology international · 2026Review
- Gut-brain nexus: Mapping multimodal links to neurodegeneration at biobank scale.Science advances · 2025Article
- Vitamin D and focal brain atrophy in PD with non-dementia: a VBM study.Frontiers in human neuroscience · 2024Article
- Relationship between serum lipids and depression: A cross sectional survey among adults in Haryana, India.Indian journal of psychiatry · 2023Article
- Corresponding risk factors between cognitive impairment and type 1 diabetes mellitus: A narrative review.Heliyon · 2022Review
- Neurocognitive outcomes in long-term survivors of Wilms tumor: a report from the St. Jude Lifetime Cohort.Journal of cancer survivorship : research and practice · 2019Article
- TDP-43 proteinopathy in aging: Associations with risk-associated gene variants and with brain parenchymal thyroid hormone levels.Neurobiology of disease · 2019Article
- Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults.Neurobiology of aging · 2018Article
- Associations between waist circumference, metabolic risk and executive function in adolescents: A cross-sectional mediation analysis.PloS one · 2018Article
- Alcohol consumption and gastric cancer risk: a meta-analysis of prospective cohort studies.Oncotarget · 2017Article
- Articles in Endocrinology and Metabolism in 2016.Endocrinology and metabolism (Seoul, Korea) · 2017Article
- Genomics and CSF analyses implicate thyroid hormone in hippocampal sclerosis of aging.Acta neuropathologica · 2016Article
- Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- Cytokines and Cytokine Receptors Involved in the Pathogenesis of Alzheimer's Disease.Journal of clinical & cellular immunology · 2016Article
- Role of the Orexin System on the Hypothalamus-Pituitary-Thyroid Axis.Frontiers in neural circuits · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive impairment, including Alzheimer's disease and other kinds of dementia, is a major health problem in older adults worldwide. Although numerous investigators have attempted to develop effective treatment modalities or drugs, there is no reasonably efficacious strategy for preventing or recovering from cognitive impairment. Therefore, modifiable risk factors for cognitive impairment have received attention, and the growing literature of metabolic risk factors for cognitive impairment has expanded from epidemiology to molecular pathogenesis and therapeutic management. This review focuses on the epidemiological evidence for the association between cognitive impairment and several endocrine risk factors, including insulin resistance, dyslipidemia, thyroid dysfunction, vitamin D deficiency, and subclinical atherosclerosis. Researches suggesting possible mechanisms for this association are reviewed. The research investigating modifiable endocrine risk factors for cognitive impairment provides clues for understanding the pathogenesis of cognitive impairment and developing novel treatment modalities. However, so far, interventional studies investigating the beneficial effect of the "modification" of these "modifiable risk factors" on cognitive impairment have reported variable results. Therefore, well-designed, randomized prospective interventional studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.